ArticleCureus2025
A Case of Simultaneous Overlapping Cancer of the Pancreatic Head and Gastric Body Managed With Pancreaticoduodenectomy and Total Gastrectomy in Two Stages.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Simultaneous overlapping cancers are defined as two or more primary malignancies diagnosed within six months of each other. The treatment strategy is highly individualized and depends on the localization and progression of each cancer. Although radical surgery is sometimes performed at the first instance, patients might be hesitant to undergo extensive resection due to the risk of surgical complications, depending on their condition. Herein, we describe the case of an 80-year-old male patient, diagnosed with concurrent pancreatic head and upper gastric cancer. He underwent a two-stage surgical treatment with favorable results. The patient was initially diagnosed with gastric cancer (cT1b, cN0, cM0, cStage1) and pancreatic head cancer (cT1, cN0, cM0, cStage1A) based on gastrointestinal endoscopy and computed tomography findings. Due to the highly invasive nature of simultaneous surgical resection, the patient opted to avoid a one-stage surgical resection. Furthermore, the treatment plan prioritized surgery for pancreatic cancer, which included subtotal stomach-preserving pancreaticoduodenectomy, m-Child reconstruction, and the Blumgart method. Postoperative pathology showed a pT3 (with duodenal invasion), pN0, cM0, and pStage2A pancreatic cancer. The patient received S-1 (tegafur/gimeracil/oteracil potassium) as an adjuvant chemotherapy for pancreatic cancer. This treatment resulted in a significant shrinkage of the gastric cancer after three months. However, one year after the surgery, the gastric cancer progressed, spreading from the upper gastric body to the middle. Despite administering two courses of S-1, it did not shrink. A total gastrectomy with Roux-en-Y reconstruction was performed, and the pathological findings indicated ypT1b, ypN0, ycM0, and ypStage1A gastric cancer. The patient remained alive even 31 months after the surgery, without recurrence. Our patient was an older adult, raising concerns about the complications with one-stage surgical resection. We successfully managed the patient by adopting a two-stage surgical approach with adjuvant chemotherapy in between. It resulted in recurrence-free survival at 31 months after the operation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.